Table 1

Agent	Type	Indication	Most common skin toxicities
Cetuximab (Erbitux)	Chimeric (mouse/human) monoclonal antibody	Metastatic colorectal cancer and head and neck cancer	Rash (Monomorphous erythematous maculopapular, follicular, or pustolar lesions which may be associated with pruritus/tenderness) Paronychia and ﬁssuring (Painful periungual granulation-type or friable pyogenic granuloma-like changes, associated with erythema, swelling, and ﬁssuring of lateral nailfolds and/or distal ﬁnger tufts) Hair changes (Alopecia and curlier, ﬁner and more brittle hair on scalp and extremities; trychomegalia and curling of eyebrows and hypertrichosis of the face) Dry skin (Diﬀuse ﬁne scaling) Mucositis (Mucositis, stomatitis, and aphthous ulcers
Panitumumab (Vectibix)	Fully human monoclonal antibody	Metastatic colorectal cancer with disease progression despite prior treatment in patients with non-mutated (wild-type) KRAS
Nimotuzumab (CIMAher)	Humanized monoclonal antibody	High grade glioma, esophagus and head and neck tumor patients
Erlotinib (Tarceva)	Selective oral inhibitor of EGFR tyrosine kinase	Locally advanced or metastatic non-small cell lung cancer after the failure of prior chemotherapy and in combination with gemcitabine for locally advanced, unresectable or metastatic pancreatic cancer
Gefitinib (Iressa)	Selective oral inhibitor of EGFR tyrosine kinase	Locally advanced or metastatic non-small cell lung cancer
EGF vaccine (CIMAvax)	Human recombinant Epidermal Growth Factor (EGF) chemically conjugated to a carrier protein from Neisseria meningitides	Advance patients with non-small cell lung cancer
Her-1 Vaccine	Extracellular domain of human EGFR/VSSP	Hormone refractory prostatic cancer patients

Table 1: Characteristics and dermatologic reactions associated with anti-epidermal growth factor/epidermal growth factor receptor therapeutic anti-cancer drugs.